Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Phase I Triazine Triepoxide (Henkel's Compound, NSC-296934)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
over 18
NCI-W82-0241
2.
Phase I and Pharmacologic Study of Triazine Triepoxide (NSC-296934) Administered on Single-Day and on Daily-for-5-Day Schedules
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
no age specified
NCI-W81-1034
Last Modified:
4/1/1989
3.
Phase I Trial of Intraperitoneal Teroxirone in Patients with Metastatic Solid Tumor Largely Confined to the Abdominal Cavity (Summary Last Modified 04/89)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI
UMCC-8802
NCI-T88-0078C, T88-0078
Last Modified:
4/1/1991
4.
Phase I Study of Intraperitoneal Teroxirone in Patients with Advanced Malignancies Principally Confined to the Peritoneal Cavity (Summary Last Modified 04/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI
MSKCC-90166
NCI-T91-0002C, T91-0002
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute